Pharma & Healthcare
Global Single-target Anti-VEGF Drugs Market Research Report 2026
- Mar 17, 26
- ID: 741398
- Pages: 112
- Figures: 116
- Views: 2
This report delivers a comprehensive overview of the global Single-target Anti-VEGF Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Single-target Anti-VEGF Drugs. The Single-target Anti-VEGF Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Single-target Anti-VEGF Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Single-target Anti-VEGF Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Novartis
Coherus BioSciences
Regeneron Pharmaceuticals
Samsung Bioepis
Biocon Biologics
Chengdu Kanghong Pharmaceutical
Segment by Type
Aflibercept
Conbercept
Ranibizumab
Brolucizumab
Faricimab
Other
by Application
Age-related Macular Degeneration
Diabetic Retinopathy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Single-target Anti-VEGF Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Single-target Anti-VEGF Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Single-target Anti-VEGF Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Single-target Anti-VEGF Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Novartis
Coherus BioSciences
Regeneron Pharmaceuticals
Samsung Bioepis
Biocon Biologics
Chengdu Kanghong Pharmaceutical
Segment by Type
Aflibercept
Conbercept
Ranibizumab
Brolucizumab
Faricimab
Other
by Application
Age-related Macular Degeneration
Diabetic Retinopathy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Single-target Anti-VEGF Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Single-target Anti-VEGF Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Single-target Anti-VEGF Drugs Market Overview
1.1 Product Definition
1.2 Single-target Anti-VEGF Drugs by Type
1.2.1 Global Single-target Anti-VEGF Drugs Market Value by Type: 2025 vs 2032
1.2.2 Aflibercept
1.2.3 Conbercept
1.2.4 Ranibizumab
1.2.5 Brolucizumab
1.2.6 Faricimab
1.2.7 Other
1.3 Single-target Anti-VEGF Drugs by Application
1.3.1 Global Single-target Anti-VEGF Drugs Market Value by Application: 2025 vs 2032
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Retinopathy
1.3.4 Other
1.4 Global Single-target Anti-VEGF Drugs Market Size Estimates and Forecasts
1.4.1 Global Single-target Anti-VEGF Drugs Revenue 2021–2032
1.4.2 Global Single-target Anti-VEGF Drugs Sales 2021–2032
1.4.3 Global Single-target Anti-VEGF Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Single-target Anti-VEGF Drugs Market Competition by Manufacturers
2.1 Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Single-target Anti-VEGF Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Single-target Anti-VEGF Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Single-target Anti-VEGF Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Single-target Anti-VEGF Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Single-target Anti-VEGF Drugs, Date of Entry into the Industry
2.8 Global Single-target Anti-VEGF Drugs Market Competitive Situation and Trends
2.8.1 Global Single-target Anti-VEGF Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Single-target Anti-VEGF Drugs Players Market Share by Revenue
2.8.3 Global Single-target Anti-VEGF Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Single-target Anti-VEGF Drugs Market Scenario by Region
3.1 Global Single-target Anti-VEGF Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Single-target Anti-VEGF Drugs Sales by Region: 2021–2032
3.2.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2021–2026
3.2.2 Global Single-target Anti-VEGF Drugs Sales by Region: 2027–2032
3.3 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021–2032
3.3.1 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021–2026
3.3.2 Global Single-target Anti-VEGF Drugs Revenue by Region: 2027–2032
3.4 North America Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.4.1 North America Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.4.3 North America Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.5.1 Europe Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.5.3 Europe Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Single-target Anti-VEGF Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Single-target Anti-VEGF Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Single-target Anti-VEGF Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.7.1 Latin America Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.7.3 Latin America Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021–2032)
4.1.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021–2026)
4.1.2 Global Single-target Anti-VEGF Drugs Sales by Type (2027–2032)
4.1.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021–2032)
4.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2021–2032)
4.2.1 Global Single-target Anti-VEGF Drugs Revenue by Type (2021–2026)
4.2.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2027–2032)
4.2.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Single-target Anti-VEGF Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021–2032)
5.1.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021–2026)
5.1.2 Global Single-target Anti-VEGF Drugs Sales by Application (2027–2032)
5.1.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021–2032)
5.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2021–2032)
5.2.1 Global Single-target Anti-VEGF Drugs Revenue by Application (2021–2026)
5.2.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2027–2032)
5.2.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Single-target Anti-VEGF Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Company Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
6.4 Regeneron Pharmaceuticals
6.4.1 Regeneron Pharmaceuticals Company Information
6.4.2 Regeneron Pharmaceuticals Description and Business Overview
6.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
6.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.5 Samsung Bioepis
6.5.1 Samsung Bioepis Company Information
6.5.2 Samsung Bioepis Description and Business Overview
6.5.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
6.5.5 Samsung Bioepis Recent Developments/Updates
6.6 Biocon Biologics
6.6.1 Biocon Biologics Company Information
6.6.2 Biocon Biologics Description and Business Overview
6.6.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
6.6.5 Biocon Biologics Recent Developments/Updates
6.7 Chengdu Kanghong Pharmaceutical
6.7.1 Chengdu Kanghong Pharmaceutical Company Information
6.7.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.7.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
6.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Single-target Anti-VEGF Drugs Industry Chain Analysis
7.2 Single-target Anti-VEGF Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Single-target Anti-VEGF Drugs Production Mode & Process Analysis
7.4 Single-target Anti-VEGF Drugs Sales and Marketing
7.4.1 Single-target Anti-VEGF Drugs Sales Channels
7.4.2 Single-target Anti-VEGF Drugs Distributors
7.5 Single-target Anti-VEGF Drugs Customer Analysis
8 Single-target Anti-VEGF Drugs Market Dynamics
8.1 Single-target Anti-VEGF Drugs Industry Trends
8.2 Single-target Anti-VEGF Drugs Market Drivers
8.3 Single-target Anti-VEGF Drugs Market Challenges
8.4 Single-target Anti-VEGF Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Single-target Anti-VEGF Drugs by Type
1.2.1 Global Single-target Anti-VEGF Drugs Market Value by Type: 2025 vs 2032
1.2.2 Aflibercept
1.2.3 Conbercept
1.2.4 Ranibizumab
1.2.5 Brolucizumab
1.2.6 Faricimab
1.2.7 Other
1.3 Single-target Anti-VEGF Drugs by Application
1.3.1 Global Single-target Anti-VEGF Drugs Market Value by Application: 2025 vs 2032
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Retinopathy
1.3.4 Other
1.4 Global Single-target Anti-VEGF Drugs Market Size Estimates and Forecasts
1.4.1 Global Single-target Anti-VEGF Drugs Revenue 2021–2032
1.4.2 Global Single-target Anti-VEGF Drugs Sales 2021–2032
1.4.3 Global Single-target Anti-VEGF Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Single-target Anti-VEGF Drugs Market Competition by Manufacturers
2.1 Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Single-target Anti-VEGF Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Single-target Anti-VEGF Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Single-target Anti-VEGF Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Single-target Anti-VEGF Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Single-target Anti-VEGF Drugs, Date of Entry into the Industry
2.8 Global Single-target Anti-VEGF Drugs Market Competitive Situation and Trends
2.8.1 Global Single-target Anti-VEGF Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Single-target Anti-VEGF Drugs Players Market Share by Revenue
2.8.3 Global Single-target Anti-VEGF Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Single-target Anti-VEGF Drugs Market Scenario by Region
3.1 Global Single-target Anti-VEGF Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Single-target Anti-VEGF Drugs Sales by Region: 2021–2032
3.2.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2021–2026
3.2.2 Global Single-target Anti-VEGF Drugs Sales by Region: 2027–2032
3.3 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021–2032
3.3.1 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021–2026
3.3.2 Global Single-target Anti-VEGF Drugs Revenue by Region: 2027–2032
3.4 North America Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.4.1 North America Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.4.3 North America Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.5.1 Europe Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.5.3 Europe Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Single-target Anti-VEGF Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Single-target Anti-VEGF Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Single-target Anti-VEGF Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.7.1 Latin America Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.7.3 Latin America Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Single-target Anti-VEGF Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021–2032)
4.1.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021–2026)
4.1.2 Global Single-target Anti-VEGF Drugs Sales by Type (2027–2032)
4.1.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021–2032)
4.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2021–2032)
4.2.1 Global Single-target Anti-VEGF Drugs Revenue by Type (2021–2026)
4.2.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2027–2032)
4.2.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Single-target Anti-VEGF Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021–2032)
5.1.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021–2026)
5.1.2 Global Single-target Anti-VEGF Drugs Sales by Application (2027–2032)
5.1.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021–2032)
5.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2021–2032)
5.2.1 Global Single-target Anti-VEGF Drugs Revenue by Application (2021–2026)
5.2.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2027–2032)
5.2.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Single-target Anti-VEGF Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Company Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
6.4 Regeneron Pharmaceuticals
6.4.1 Regeneron Pharmaceuticals Company Information
6.4.2 Regeneron Pharmaceuticals Description and Business Overview
6.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
6.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.5 Samsung Bioepis
6.5.1 Samsung Bioepis Company Information
6.5.2 Samsung Bioepis Description and Business Overview
6.5.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
6.5.5 Samsung Bioepis Recent Developments/Updates
6.6 Biocon Biologics
6.6.1 Biocon Biologics Company Information
6.6.2 Biocon Biologics Description and Business Overview
6.6.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
6.6.5 Biocon Biologics Recent Developments/Updates
6.7 Chengdu Kanghong Pharmaceutical
6.7.1 Chengdu Kanghong Pharmaceutical Company Information
6.7.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.7.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
6.7.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Single-target Anti-VEGF Drugs Industry Chain Analysis
7.2 Single-target Anti-VEGF Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Single-target Anti-VEGF Drugs Production Mode & Process Analysis
7.4 Single-target Anti-VEGF Drugs Sales and Marketing
7.4.1 Single-target Anti-VEGF Drugs Sales Channels
7.4.2 Single-target Anti-VEGF Drugs Distributors
7.5 Single-target Anti-VEGF Drugs Customer Analysis
8 Single-target Anti-VEGF Drugs Market Dynamics
8.1 Single-target Anti-VEGF Drugs Industry Trends
8.2 Single-target Anti-VEGF Drugs Market Drivers
8.3 Single-target Anti-VEGF Drugs Market Challenges
8.4 Single-target Anti-VEGF Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Single-target Anti-VEGF Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Single-target Anti-VEGF Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Single-target Anti-VEGF Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Single-target Anti-VEGF Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Single-target Anti-VEGF Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Single-target Anti-VEGF Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Single-target Anti-VEGF Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Single-target Anti-VEGF Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Single-target Anti-VEGF Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Single-target Anti-VEGF Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Single-target Anti-VEGF Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Single-target Anti-VEGF Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Single-target Anti-VEGF Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Single-target Anti-VEGF Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Single-target Anti-VEGF Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Single-target Anti-VEGF Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Single-target Anti-VEGF Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Single-target Anti-VEGF Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Single-target Anti-VEGF Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Single-target Anti-VEGF Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Single-target Anti-VEGF Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Single-target Anti-VEGF Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis Single-target Anti-VEGF Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences Single-target Anti-VEGF Drugs Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Regeneron Pharmaceuticals Company Information
Table 86. Regeneron Pharmaceuticals Description and Business Overview
Table 87. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product
Table 89. Regeneron Pharmaceuticals Recent Developments/Updates
Table 90. Samsung Bioepis Company Information
Table 91. Samsung Bioepis Description and Business Overview
Table 92. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Samsung Bioepis Single-target Anti-VEGF Drugs Product
Table 94. Samsung Bioepis Recent Developments/Updates
Table 95. Biocon Biologics Company Information
Table 96. Biocon Biologics Description and Business Overview
Table 97. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Biocon Biologics Single-target Anti-VEGF Drugs Product
Table 99. Biocon Biologics Recent Developments/Updates
Table 100. Chengdu Kanghong Pharmaceutical Company Information
Table 101. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 102. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product
Table 104. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Single-target Anti-VEGF Drugs Distributors List
Table 108. Single-target Anti-VEGF Drugs Customers List
Table 109. Single-target Anti-VEGF Drugs Market Trends
Table 110. Single-target Anti-VEGF Drugs Market Drivers
Table 111. Single-target Anti-VEGF Drugs Market Challenges
Table 112. Single-target Anti-VEGF Drugs Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Product Picture of Single-target Anti-VEGF Drugs
Figure 2. Global Single-target Anti-VEGF Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Single-target Anti-VEGF Drugs Market Share by Type: 2025 & 2032
Figure 4. Aflibercept Product Picture
Figure 5. Conbercept Product Picture
Figure 6. Ranibizumab Product Picture
Figure 7. Brolucizumab Product Picture
Figure 8. Faricimab Product Picture
Figure 9. Other Product Picture
Figure 10. Global Single-target Anti-VEGF Drugs Market Value by Application (US$ Million), 2021–2032
Figure 11. Global Single-target Anti-VEGF Drugs Market Share by Application: 2025 & 2032
Figure 12. Age-related Macular Degeneration
Figure 13. Diabetic Retinopathy
Figure 14. Other
Figure 15. Global Single-target Anti-VEGF Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Single-target Anti-VEGF Drugs Market Size (US$ Million), 2021–2032
Figure 17. Global Single-target Anti-VEGF Drugs Sales (K Units), 2021–2032
Figure 18. Global Single-target Anti-VEGF Drugs Average Price (US$/Unit), 2021–2032
Figure 19. Single-target Anti-VEGF Drugs Report Years Considered
Figure 20. Single-target Anti-VEGF Drugs Sales Share by Manufacturers in 2025
Figure 21. Global Single-target Anti-VEGF Drugs Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global Single-target Anti-VEGF Drugs Players: Market Share by Revenue in Single-target Anti-VEGF Drugs in 2025
Figure 23. Single-target Anti-VEGF Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global Single-target Anti-VEGF Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 26. North America Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 27. United States Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 30. Europe Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 31. Germany Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific Single-target Anti-VEGF Drugs Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021–2032)
Figure 38. China Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 46. Latin America Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 47. Mexico Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 53. Turkey Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of Single-target Anti-VEGF Drugs by Type (2021–2032)
Figure 57. Global Revenue Market Share of Single-target Anti-VEGF Drugs by Type (2021–2032)
Figure 58. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of Single-target Anti-VEGF Drugs by Application (2021–2032)
Figure 60. Global Revenue Market Share of Single-target Anti-VEGF Drugs by Application (2021–2032)
Figure 61. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Application (2021–2032)
Figure 62. Single-target Anti-VEGF Drugs Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Single-target Anti-VEGF Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Single-target Anti-VEGF Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Single-target Anti-VEGF Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Single-target Anti-VEGF Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Single-target Anti-VEGF Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Single-target Anti-VEGF Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Single-target Anti-VEGF Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Single-target Anti-VEGF Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Single-target Anti-VEGF Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Single-target Anti-VEGF Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Single-target Anti-VEGF Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Single-target Anti-VEGF Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Single-target Anti-VEGF Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Single-target Anti-VEGF Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Single-target Anti-VEGF Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Single-target Anti-VEGF Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Single-target Anti-VEGF Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Single-target Anti-VEGF Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Single-target Anti-VEGF Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Single-target Anti-VEGF Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Single-target Anti-VEGF Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Single-target Anti-VEGF Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Single-target Anti-VEGF Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Single-target Anti-VEGF Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Single-target Anti-VEGF Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis Single-target Anti-VEGF Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences Single-target Anti-VEGF Drugs Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Regeneron Pharmaceuticals Company Information
Table 86. Regeneron Pharmaceuticals Description and Business Overview
Table 87. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product
Table 89. Regeneron Pharmaceuticals Recent Developments/Updates
Table 90. Samsung Bioepis Company Information
Table 91. Samsung Bioepis Description and Business Overview
Table 92. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Samsung Bioepis Single-target Anti-VEGF Drugs Product
Table 94. Samsung Bioepis Recent Developments/Updates
Table 95. Biocon Biologics Company Information
Table 96. Biocon Biologics Description and Business Overview
Table 97. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Biocon Biologics Single-target Anti-VEGF Drugs Product
Table 99. Biocon Biologics Recent Developments/Updates
Table 100. Chengdu Kanghong Pharmaceutical Company Information
Table 101. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 102. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product
Table 104. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Single-target Anti-VEGF Drugs Distributors List
Table 108. Single-target Anti-VEGF Drugs Customers List
Table 109. Single-target Anti-VEGF Drugs Market Trends
Table 110. Single-target Anti-VEGF Drugs Market Drivers
Table 111. Single-target Anti-VEGF Drugs Market Challenges
Table 112. Single-target Anti-VEGF Drugs Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
Table 116. Authors List of This Report
List of Figures
Figure 1. Product Picture of Single-target Anti-VEGF Drugs
Figure 2. Global Single-target Anti-VEGF Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Single-target Anti-VEGF Drugs Market Share by Type: 2025 & 2032
Figure 4. Aflibercept Product Picture
Figure 5. Conbercept Product Picture
Figure 6. Ranibizumab Product Picture
Figure 7. Brolucizumab Product Picture
Figure 8. Faricimab Product Picture
Figure 9. Other Product Picture
Figure 10. Global Single-target Anti-VEGF Drugs Market Value by Application (US$ Million), 2021–2032
Figure 11. Global Single-target Anti-VEGF Drugs Market Share by Application: 2025 & 2032
Figure 12. Age-related Macular Degeneration
Figure 13. Diabetic Retinopathy
Figure 14. Other
Figure 15. Global Single-target Anti-VEGF Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Single-target Anti-VEGF Drugs Market Size (US$ Million), 2021–2032
Figure 17. Global Single-target Anti-VEGF Drugs Sales (K Units), 2021–2032
Figure 18. Global Single-target Anti-VEGF Drugs Average Price (US$/Unit), 2021–2032
Figure 19. Single-target Anti-VEGF Drugs Report Years Considered
Figure 20. Single-target Anti-VEGF Drugs Sales Share by Manufacturers in 2025
Figure 21. Global Single-target Anti-VEGF Drugs Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global Single-target Anti-VEGF Drugs Players: Market Share by Revenue in Single-target Anti-VEGF Drugs in 2025
Figure 23. Single-target Anti-VEGF Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global Single-target Anti-VEGF Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 26. North America Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 27. United States Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 30. Europe Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 31. Germany Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific Single-target Anti-VEGF Drugs Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021–2032)
Figure 38. China Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 46. Latin America Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 47. Mexico Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa Single-target Anti-VEGF Drugs Revenue Market Share by Country (2021–2032)
Figure 53. Turkey Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE Single-target Anti-VEGF Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of Single-target Anti-VEGF Drugs by Type (2021–2032)
Figure 57. Global Revenue Market Share of Single-target Anti-VEGF Drugs by Type (2021–2032)
Figure 58. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of Single-target Anti-VEGF Drugs by Application (2021–2032)
Figure 60. Global Revenue Market Share of Single-target Anti-VEGF Drugs by Application (2021–2032)
Figure 61. Global Single-target Anti-VEGF Drugs Price (US$/Unit) by Application (2021–2032)
Figure 62. Single-target Anti-VEGF Drugs Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232